WorldGSK's Covid-19 drug overcomes all Omicron mutations

GSK’s Covid-19 drug overcomes all Omicron mutations


These are the results from data from early-stage studies. GSK developed the antibody-based drug sotrovimab in collaboration with the American company Vir Biotechnology.

A week earlier, GSK announced preclinical data showing the drug was effective against the Omicron variant.

Sotrovimab is designed to target the spike protein on the surface of the virus that causes Covid-19. Omicrons are thought to have an unusually high number of mutations on this spike protein.

n

However, GSK confirmed that trial data showed the drug was effective against the 37 variants that have been identified so far.

Hal Barron, GSK’s chief scientific officer, said sotrovimab was also effective for any variant of concern.

.